Tau Therapeutics is currently investigating the use of Interlaced Therapy™ with mibefradil dihydrochloride for the treatment of metastatic melanoma. We are in late-stage pre-clinical testing and hope to enter the clinic in 12 months.
Tau Therapeutics is currently investigating the use of Interlaced Therapy™ with mibefradil dihydrochloride for the treatment of metastatic melanoma. We are in late-stage pre-clinical testing and hope to enter the clinic in 12 months.